A Phase 3 interventional study of Eptinezumab and Placebo in Cluster Headache, Episodic, sponsored by H. Lundbeck A/S. Completed at 120 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-09.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Cluster Headache with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Cluster Headache · United States.
Among the 38 studies in Cluster Headache with a site in United States, this one is the 5th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2020, is one of 10 in phase 3, and was the 28th registered.
123 studies on the registry are indexed under Cluster Headache; 26 are open to participants now.
Browse Cluster Headache studies →7 of the 38 studies in Cluster Headache with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
Stanford University · Sites in United States
Ages 18–80
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Healthy volunteers
Tobias Moeller-Bertram · Sites in United States
Ages 21+ · Healthy volunteers
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Cluster Headache studies recruiting now, 7 (39%) set no upper age limit and 6 (33%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 11 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 42 across 90 interventional studies indexed under Cluster Headache.
Median enrollment 41 across the 30 interventional studies, 1,000 across the 8 observational. Of the 27 that completed or were terminated, 16 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
H. Lundbeck A/S has 2 studies filed under Cluster Headache — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies in Cluster Headache with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
Eligible participants will be randomly assigned to receive treatment, in a blinded manner, two infusions of either eptinezumab or placebo in a cross-over manner during the Placebo-controlled Period and Active Treatment Period of the study.
The total duration of the study after randomization is 24 weeks, including a safety follow-up period of 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eptinezumab in the Placebo-controlled Period, followed by administration of placebo in the Active Treatment Period
Drug: Eptinezumab · Drug: Placebo
Placebo in the Placebo-controlled Period, followed by administration of eptinezumab in the Active Treatment Period
Drug: Eptinezumab · Drug: Placebo
Eptinezumab - concentrate for solution for infusion, intravenously
Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
Change From Baseline in the Number of Weekly Cluster Headache (CH) Attacks, Averaged Over Weeks 1-2
The participant completed a CH eDiary, daily, and recorded for each day/week whether he/she had any CH attacks. For each CH attack, the start date and time was collected. The participant recorded further daily information regarding CH characteristics and intake of acute medication for CH. CH items were assessed with a yes/no response.
Time frame: Baseline (Week 0), Weeks 1-2
Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks Over Weeks 1-2
Time frame: Baseline (Week 0), Weeks 1-2
Change From Baseline in the Number of Weekly Times an Abortive Medication Was Used, Averaged Over Weeks 1-2
Abortive medications included the use of triptans or oxygen (O2).
Time frame: Baseline (Week 0), Weeks 1-2
Change From Baseline in the Number of Daily Attacks, Averaged Over Days 1-3
Time frame: Baseline (Week 0), Days 1-3
Change From Baseline in the Number of Days With <3 Attacks Per Day, Averaged Over Weeks 1-2
Time frame: Baseline (Week 0), Weeks 1-2
Time From First Infusion of IMP to Resolution of Cluster Headache Bout Within the First 4 Weeks
Presented here is the result of the analysis of time from first infusion of IMP to resolution of cluster headache bout. The hazard ratio estimate is an estimate from the Cox model of time to resolution.
Time frame: From first infusion (Baseline, Day 0) to 4 weeks
Change From Baseline in Number of Attacks Starting ≤24 Hours After the Start of the First Infusion of IMP
Time frame: From first infusion in the placebo-controlled period (Baseline, Day 0) to 24-hours after the first infusion in the placebo-controlled period
Change From Baseline in the Daily Mean Score on 5-Point Self-Rating Pain Severity Scale, Averaged Over Days 1-3
The severity of pain was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (headache pain ratings: 0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating).
Time frame: Baseline (Week 0), Days 1-3
Change From Baseline to Week 1 in the Number of Weekly Attacks
Time frame: Baseline (Week 0), Week 1
Change From Baseline to Week 2 in the Number of Weekly Attacks
Time frame: Baseline (Week 0), Week 2
Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks in Week 1
Time frame: Baseline (Week 0), Week 1
Number of Participants With ≥30% Reduction From Baseline in Number of Weekly Attacks in Week 1
Time frame: Baseline (Week 0), Week 1
Number of Participants With ≥30% Reduction From Baseline in Number of Weekly Attacks Over Weeks 1-2
Time frame: Baseline (Week 0), Weeks 1-2
Change From Baseline in Weekly Integrated Measure of Frequency and Intensity of Pain, Averaged Over Weeks 1-2
The weekly integrated measure of frequency and intensity of pain calculates a singular numerical value for frequency and intensity of pain by adding the intensity rating (Worst pain on a 5-point Self-rating pain severity scale) for each attack during that week. The intensity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating). The total weekly score could range from 0 (no attacks and/or no pain) to no specified upper limit, with lower scores representing better outcomes.
Time frame: Baseline (Week 0), Weeks 1-2
Change From Baseline to Week 1 in Weekly Integrated Measure of Frequency and Intensity of Pain
The weekly integrated measure of frequency and intensity of pain calculates a singular numerical value for frequency and intensity of pain by adding the intensity rating (Worst pain on a 5-point Self-rating pain severity scale) for each attack during that week. The intensity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating). The total weekly score could range from 0 (no attacks and/or no pain) to no specified upper limit, with lower scores representing better outcomes.
Time frame: Baseline (Week 0), Week 1
Change From Baseline to Week 2 in Weekly Integrated Measure of Frequency and Intensity of Pain
The weekly integrated measure of frequency and intensity of pain calculates a singular numerical value for frequency and intensity of pain by adding the intensity rating (Worst pain on a 5-point Self-rating pain severity scale) for each attack during that week. The intensity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating). The total weekly score could range from 0 (no attacks and/or no pain) to no specified upper limit, with lower scores representing better outcomes.
Time frame: Baseline (Week 0), Week 2
Change From Baseline in the Number of Weekly Attacks, Averaged Over Weeks 1-4
Time frame: Baseline (Week 0), Weeks 1-4
Change From Baseline in Weekly Integrated Measure of Frequency and Intensity of Pain, Averaged Over Weeks 1-4
The weekly integrated measure of frequency and intensity of pain score calculates a singular numerical value for frequency and intensity of pain by adding the intensity rating (Worst pain on a 5-point Self-rating pain severity scale) for each attack during that week. The intensity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating). The total weekly score could range from 0 (no attacks and/or no pain) to no specified upper limit, with lower scores representing better outcomes.
Time frame: Baseline (Week 0), Weeks 1-4
Change From Baseline in the Mean Score on 5-Point Self-Rating Pain Severity Scale (Average Per Attack Over a Week) for Weeks 1, 2, 3, and 4
The severity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (headache pain ratings: 0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating).
Time frame: Baseline (Week 0), Weeks 1, 2, 3, and 4
Change From Baseline in the Number of Weekly Attacks for Each of Weeks 3 and 4
Time frame: Baseline (Week 0), Weeks 3-4
Patient Global Impression of Change (PGIC) Score at Weeks 1, 2, and 4
The PGIC is a patient-reported measure of improvement in pain sensation and quality of life scored on a scale from 1 (very much improved) to 7 (very much worse). Lower scores indicate better health status.
Time frame: Weeks 1, 2, and 4
Change From Baseline in Sleep Impact Scale (SIS) Domain Scores at Weeks 2 and 4
The SIS is a patient-reported clinical outcome assessment used to assess quality of life resulting from sleep disturbance. The SIS questionnaire includes 35 items belonging to 7 domains to assess sleep impact on: daily activities; emotional well-being; emotional impact; energy/fatigue; social well-being; mental fatigue; and satisfaction with sleep. Each item, for 6 out of the 7 domains, is rated on a 5-point scale ranging from 1 (always or all of the time) to 5 (never or none of the time), whereas satisfaction with sleep is rated on a 5-point scale ranging from 1 (very satisfied) to 5 (very dissatisfied). Each domain yields a score ranging from 0 to 100, which is presented here. A higher score for Daily Activities, Emotional Well-being, Emotional Impact, Energy/Fatigue, Social Well-being, and Mental Fatigue indicates better quality of life. A lower score for Satisfaction with Sleep indicates a higher quality of life.
Time frame: Baseline (Week 0), Weeks 2 and 4
Change From Baseline in Euroqol 5-Dimension 5-Levels (EQ-5D-5L) Visual Analogue Scale (VAS) at Weeks 2 and 4
The EQ-5D-5L VAS is a participant-reported assessment designed to measure the participant's well-being and ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline (Week 0), Weeks 2 and 4
Health Care Resource Utilization (HCRU) Score: Number of Visits to a Family Doctor/General Practitioner
Number of participants who visited a family doctor/general practitioner has been reported.
Time frame: Week 4
HCRU Score: Number of Visits to a Specialist
Number of participants who visited a specialist has been reported.
Time frame: Week 4
HCRU Score: Number of Emergency Department Visits Due to Cluster Headache
Number of participants who visited an emergency department due to CH was reported.
Time frame: Week 4
HCRU Score: Number of Hospital Admissions Due to Cluster Headache
Number of participants who were admitted to a hospital due to CH was reported.
Time frame: Week 4
HCRU Score: Number of Overnight Hospital Stays Due to Cluster Headache
Number of participants who stayed overnight in a hospital due to CH was reported.
Time frame: Week 4
Change From Baseline in the Work Productivity Activity Impairment (WPAI) Questionnaire Subscores at Week 4
The WPAI:GH2.0 is a patient self-rated clinical outcome assessment designed to provide a quantitative measure of the work productivity and activity impairment due to a health condition. The WPAI:GH2.0 assesses activities over the preceding 7 days and consists of 6 items: 1 item assesses employment (yes/no); 3 items assess the number of hours worked, the number of hours missed from work due to the participant's condition, or due to other reasons; and 2 visual numerical scales assess how much the participant's condition affects his/her productivity at work and his/her ability to complete normal daily activities. Each item (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) was calculated into an impairment percentage ranging from 0 to 100%, with higher numbers indicating greater impairment and less productivity (i.e. worse outcomes). Change from baseline for each item is shown here.
Time frame: Baseline (Week 0), Week 4
| Milestone | Eptinezumab | Placebo | Delayed Start Period: Placebo to Eptinezumab | Delayed Start Period: Eptinezumab to Placebo |
|---|---|---|---|---|
| Started | 113 | 118 | 0 | 0 |
| Received at least 1 dose of study drug | 112 | 117 | 0 | 0 |
| Completed | 108 | 107 | 0 | 0 |
| Not completed | 5 | 11 | 0 | 0 |
| Withdrew: Randomized, not treated | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 6 | 0 | 0 |
| Withdrew: Other reasons | 0 | 1 | 0 | 0 |
| Milestone | Eptinezumab | Placebo | Delayed Start Period: Placebo to Eptinezumab | Delayed Start Period: Eptinezumab to Placebo |
|---|---|---|---|---|
| Started | 0 | 0 | 107 | 108 |
| Received at least 1 dose of study drug | 0 | 0 | 107 | 108 |
| Completed | 0 | 0 | 101 | 100 |
| Not completed | 0 | 0 | 6 | 8 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 1 |
| Withdrew: Other reasons | 0 | 0 | 1 | 0 |
The participant completed a CH eDiary, daily, and recorded for each day/week whether he/she had any CH attacks. For each CH attack, the start date and time was collected. The participant recorded further daily information regarding CH characteristics and intake of acute medication for CH. CH items were assessed with a yes/no response.
| Number of Weekly Attacks | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in the Number of Weekly Cluster Headache (CH) Attacks, Averaged Over Weeks 1-2 | -4.0 ± 0.93 | -4.6 ± 0.89 |
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks Over Weeks 1-2 | 44 | 37 |
Abortive medications included the use of triptans or oxygen (O2).
| Abortive therapy use per week | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in the Number of Weekly Times an Abortive Medication Was Used, Averaged Over Weeks 1-2 | -2.54 ± 0.98 | -3.55 ± 0.93 |
| Attacks per day | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in the Number of Daily Attacks, Averaged Over Days 1-3 | -0.22 ± 0.16 | -0.35 ± 0.15 |
| Days | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in the Number of Days With <3 Attacks Per Day, Averaged Over Weeks 1-2 | 0.60 ± 0.20 | 0.82 ± 0.19 |
Presented here is the result of the analysis of time from first infusion of IMP to resolution of cluster headache bout. The hazard ratio estimate is an estimate from the Cox model of time to resolution.
| days | Eptinezumab | Placebo |
|---|---|---|
| Time From First Infusion of IMP to Resolution of Cluster Headache Bout Within the First 4 Weeks | NA (NA to NA) | NA (NA to NA) |
| Number of attacks | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in Number of Attacks Starting ≤24 Hours After the Start of the First Infusion of IMP | 2.07 ± 0.18 | 1.96 ± 0.17 |
The severity of pain was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (headache pain ratings: 0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating).
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in the Daily Mean Score on 5-Point Self-Rating Pain Severity Scale, Averaged Over Days 1-3 | -0.30 ± 0.10 | -0.18 ± 0.09 |
| Attacks per week | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline to Week 1 in the Number of Weekly Attacks | -2.62 ± 0.95 | -3.71 ± 0.90 |
| Attacks per week | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline to Week 2 in the Number of Weekly Attacks | -5.44 ± 1.00 | -5.64 ± 0.96 |
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Number of Participants With ≥50% Reduction From Baseline in Number of Weekly Attacks in Week 1 | 36 | 28 |
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Number of Participants With ≥30% Reduction From Baseline in Number of Weekly Attacks in Week 1 | 48 | 50 |
| Participants | Eptinezumab | Placebo |
|---|---|---|
| Number of Participants With ≥30% Reduction From Baseline in Number of Weekly Attacks Over Weeks 1-2 | 59 | 53 |
The weekly integrated measure of frequency and intensity of pain calculates a singular numerical value for frequency and intensity of pain by adding the intensity rating (Worst pain on a 5-point Self-rating pain severity scale) for each attack during that week. The intensity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating). The total weekly score could range from 0 (no attacks and/or no pain) to no specified upper limit, with lower scores representing better outcomes.
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in Weekly Integrated Measure of Frequency and Intensity of Pain, Averaged Over Weeks 1-2 | -13.39 ± 2.56 | -14.46 ± 2.43 |
The weekly integrated measure of frequency and intensity of pain calculates a singular numerical value for frequency and intensity of pain by adding the intensity rating (Worst pain on a 5-point Self-rating pain severity scale) for each attack during that week. The intensity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating). The total weekly score could range from 0 (no attacks and/or no pain) to no specified upper limit, with lower scores representing better outcomes.
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline to Week 1 in Weekly Integrated Measure of Frequency and Intensity of Pain | -10.58 ± 2.55 | -11.96 ± 2.42 |
The weekly integrated measure of frequency and intensity of pain calculates a singular numerical value for frequency and intensity of pain by adding the intensity rating (Worst pain on a 5-point Self-rating pain severity scale) for each attack during that week. The intensity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating). The total weekly score could range from 0 (no attacks and/or no pain) to no specified upper limit, with lower scores representing better outcomes.
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline to Week 2 in Weekly Integrated Measure of Frequency and Intensity of Pain | -16.20 ± 2.73 | -16.95 ± 2.61 |
| Attacks per week | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in the Number of Weekly Attacks, Averaged Over Weeks 1-4 | -5.95 ± 0.92 | -5.78 ± 0.88 |
The weekly integrated measure of frequency and intensity of pain score calculates a singular numerical value for frequency and intensity of pain by adding the intensity rating (Worst pain on a 5-point Self-rating pain severity scale) for each attack during that week. The intensity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating). The total weekly score could range from 0 (no attacks and/or no pain) to no specified upper limit, with lower scores representing better outcomes.
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Change From Baseline in Weekly Integrated Measure of Frequency and Intensity of Pain, Averaged Over Weeks 1-4 | -17.81 ± 2.50 | -16.81 ± 2.37 |
The severity of pain for each attack was rated on an ordinal scale that ranged from 0 to 4 with higher scores indicating more headache pain (headache pain ratings: 0 = none/barely any pain; 1 = mild; 2 = moderate; 3 = severe; 4 = excruciating).
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Week 1 | -0.33 ± 0.09 | -0.24 ± 0.08 |
| Week 2 | -0.46 ± 0.10 | -0.35 ± 0.09 |
| Week 3 | -0.56 ± 0.11 | -0.31 ± 0.10 |
| Week 4 | -0.51 ± 0.11 | -0.42 ± 0.10 |
| Attacks per week | Eptinezumab | Placebo |
|---|---|---|
| Week 3 | -7.35 ± 0.98 | -6.60 ± 0.94 |
| Week 4 | -8.37 ± 1.11 | -7.15 ± 1.07 |
The PGIC is a patient-reported measure of improvement in pain sensation and quality of life scored on a scale from 1 (very much improved) to 7 (very much worse). Lower scores indicate better health status.
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Week 1 | 3.19 ± 0.16 | 3.55 ± 0.15 |
| Week 2 | 2.92 ± 0.17 | 3.44 ± 0.16 |
| Week 4 | 2.85 ± 0.18 | 3.23 ± 0.17 |
The SIS is a patient-reported clinical outcome assessment used to assess quality of life resulting from sleep disturbance. The SIS questionnaire includes 35 items belonging to 7 domains to assess sleep impact on: daily activities; emotional well-being; emotional impact; energy/fatigue; social well-being; mental fatigue; and satisfaction with sleep. Each item, for 6 out of the 7 domains, is rated on a 5-point scale ranging from 1 (always or all of the time) to 5 (never or none of the time), whereas satisfaction with sleep is rated on a 5-point scale ranging from 1 (very satisfied) to 5 (very dissatisfied). Each domain yields a score ranging from 0 to 100, which is presented here. A higher score for Daily Activities, Emotional Well-being, Emotional Impact, Energy/Fatigue, Social Well-being, and Mental Fatigue indicates better quality of life. A lower score for Satisfaction with Sleep indicates a higher quality of life.
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Daily Activities - Week 2 | 16.83 ± 3.08 | 8.93 ± 3.06 |
| Daily Activities - Week 4 | 24.82 ± 3.19 | 13.97 ± 3.08 |
| Emotional Well-being - Week 2 | 14.85 ± 2.84 | 6.04 ± 2.81 |
| Emotional Well-being - Week 4 | 22.77 ± 3.07 | 12.22 ± 2.97 |
| Energy/Fatigue - Week 2 | 18.16 ± 3.23 | 8.03 ± 3.19 |
| Energy/Fatigue - Week 4 | 24.16 ± 3.47 | 14.68 ± 3.36 |
| Mental Fatigue - Week 2 | 9.04 ± 2.66 | 4.15 ± 2.64 |
| Mental Fatigue - Week 4 | 15.15 ± 2.91 | 8.00 ± 2.81 |
| Emotional Impact - Week 2 | 14.39 ± 3.02 | 6.00 ± 3.00 |
| Emotional Impact - Week 4 | 23.09 ± 3.29 | 13.36 ± 3.18 |
| Social Well-being - Week 2 | 15.22 ± 3.37 | 6.92 ± 3.35 |
| Social Well-being - Week 4 | 23.74 ± 3.46 | 13.91 ± 3.35 |
| Satisfaction with Sleep - Week 2 | -11.41 ± 2.75 | -6.06 ± 2.73 |
| Satisfaction with Sleep - Week 4 | -19.60 ± 2.88 | -9.63 ± 2.78 |
The EQ-5D-5L VAS is a participant-reported assessment designed to measure the participant's well-being and ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Week 2 | 8.21 ± 2.79 | 3.47 ± 2.86 |
| Week 4 | 13.49 ± 2.80 | 5.73 ± 2.77 |
Number of participants who visited a family doctor/general practitioner has been reported.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| 0 visits | 85 | 85 |
| 1 visit | 9 | 10 |
| 2 visits | 1 | 6 |
| 3 visits | 3 | 1 |
| 5 visits | 1 | 1 |
| 6 visits | 1 | 1 |
Number of participants who visited a specialist has been reported.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| 0 visits | 77 | 68 |
| 1 visit | 11 | 18 |
| 2 visits | 6 | 14 |
| 3 visits | 4 | 2 |
| 4 visits | 2 | 2 |
Number of participants who visited an emergency department due to CH was reported.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| 0 visits | 98 | 99 |
| 1 visit | 1 | 2 |
| 2 visits | 1 | 2 |
| 3 visits | 0 | 1 |
Number of participants who were admitted to a hospital due to CH was reported.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| 0 admissions | 97 | 102 |
| 1 admission | 1 | 0 |
| 2 admissions | 2 | 1 |
| 3 admissions | 0 | 1 |
Number of participants who stayed overnight in a hospital due to CH was reported.
| Participants | Eptinezumab | Placebo |
|---|---|---|
| 0 overnight hospital stays | 99 | 104 |
| 5 overnight hospital stays | 1 | 0 |
The WPAI:GH2.0 is a patient self-rated clinical outcome assessment designed to provide a quantitative measure of the work productivity and activity impairment due to a health condition. The WPAI:GH2.0 assesses activities over the preceding 7 days and consists of 6 items: 1 item assesses employment (yes/no); 3 items assess the number of hours worked, the number of hours missed from work due to the participant's condition, or due to other reasons; and 2 visual numerical scales assess how much the participant's condition affects his/her productivity at work and his/her ability to complete normal daily activities. Each item (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) was calculated into an impairment percentage ranging from 0 to 100%, with higher numbers indicating greater impairment and less productivity (i.e. worse outcomes). Change from baseline for each item is shown here.
| score on a scale | Eptinezumab | Placebo |
|---|---|---|
| Absenteeism | -13.71 ± 3.95 | -4.37 ± 3.74 |
| Presenteeism | -19.29 ± 4.81 | -11.03 ± 4.68 |
| Work productivity loss | -23.59 ± 5.34 | -13.68 ± 5.20 |
| Activity impairment | -25.84 ± 3.70 | -15.82 ± 3.58 |
Collected over From date of first dose of IMP to 20 weeks after last dose (up to 24 weeks). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Period: Eptinezumab | 0/112 (0%) | 2/112 (1.8%) | 10/112 (8.9%) |
| Placebo-controlled Period: Placebo | 0/117 (0%) | 0/117 (0%) | 9/117 (7.7%) |
| Delayed Start Period: Eptinezumab to Placebo | 0/108 (0%) | 2/108 (1.9%) | 13/108 (12%) |
| Delayed Start Period: Placebo to Eptinezumab | 0/107 (0%) | 1/107 (0.9%) | 9/107 (8.4%) |
| Event | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo | Delayed Start Period: Eptinezumab to Placebo | Delayed Start Period: Placebo to Eptinezumab |
|---|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 0/112 | 0/117 | 0/108 | 1/107 |
| Meningitis enteroviralInfections and infestations | 0/112 | 0/117 | 1/108 | 0/107 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/112 | 0/117 | 1/108 | 0/107 |
| HypersensitivityImmune system disorders | 1/112 | 0/117 | 0/108 | 0/107 |
| Urinary incontinenceRenal and urinary disorders | 1/112 | 0/117 | 0/108 | 0/107 |
| CystoceleReproductive system and breast disorders | 1/112 | 0/117 | 0/108 | 0/107 |
| Event | Placebo-controlled Period: Eptinezumab | Placebo-controlled Period: Placebo | Delayed Start Period: Eptinezumab to Placebo | Delayed Start Period: Placebo to Eptinezumab |
|---|---|---|---|---|
| COVID-19Infections and infestations | 1/112 | 3/117 | 7/108 | 2/107 |
| NasopharyngitisInfections and infestations | 2/112 | 3/117 | 2/108 | 6/107 |
| ConstipationGastrointestinal disorders | 4/112 | 2/117 | 3/108 | 0/107 |
| FatigueGeneral disorders | 4/112 | 1/117 | 0/108 | 1/107 |
| Urinary tract infectionInfections and infestations | 0/112 | 1/117 | 3/108 | 0/107 |
The all-participants-randomized-set (APRS) included all randomized participants. The all-participants-treated set (APTS) included all randomized participants who received infusion with double-blind investigational medicinal product (IMP). Demographic characteristics were collected for the APTS and study-specific characteristics were collected for the APRS.
| Age, Continuous(years) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Mean | 44.17 ± 11.099 | 43.94 ± 11.019 | 44.05 ± 11.035 |
| Sex: Female, Male(Participants) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Female | 27 | 24 | 51 |
| Male | 85 | 93 | 178 |
| Race/Ethnicity, Customized(Participants) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 97 | 103 | 200 |
| Other | 1 | 2 | 3 |
| Unknown or Not Reported | 9 | 8 | 17 |
| Number of Weekly Cluster Headache (CH) Attacks(Number of Weekly Attacks) | Eptinezumab | Placebo | Total |
|---|---|---|---|
| Mean | 15.2 ± 8.07 | 15.7 ± 8.28 | 15.4 ± 8.17 |
Showing the first 100 of 120 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Jun 2023, 29 months.
Results were first posted in Aug 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab